On Aug. 25, 2020, Intravacc announced that it had partnered with American, Buffalo, NY, based Therapyx, to further develop and optimize the worldﾒs first prophylactic vaccine against gonorrhea, NGoXIM. For this Therapyx received a $ 2.8 million Phase IIB grant in the US and has chosen to partner with Intravacc for its unique capabilities and infrastructure for the optimization of vaccines, vaccine processes and vaccine technologies.